Hyperpolarized Carbon-13 Metabolic MRI of the Human Heart

人类心脏的超极化碳 13 代谢 MRI

• 批准号: 10569034
• 负责人: Maria Roselle Abraham
• 金额: $ 48.25万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-02-15 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10569034
• 关键词: Address; Bicarbonates; Blood; Calibration; Carbohydrates; Carbon; Cardiac; Cardiomyopathies; Cardiovascular system; Cause of Death; Cessation of life; Clinical Research; Contrast Media; Data; Development; Diabetes Mellitus; Diagnosis; Diastolic heart failure; Evaluation; Exercise; Fatty Acids; Glucose; Glycolysis; Heart; Heart Diseases; Heart failure; Human; Hypertrophic Cardiomyopathy; Image; Imaging Techniques; Imaging technology; Inherited; Injections; Intervention; Ionizing radiation; Ischemia; Ketone Bodies; MRI Scans; Magnetic Resonance Imaging; Measurement; Measures; Metabolic; Metabolic Pathway; Metabolism; Methods; Modeling; Monitor; Morphologic artifacts; Motion; Myocardium; Oral; Pathogenesis; Patients; Performance; Pharmaceutical Preparations; Play; Positron-Emission Tomography; Preparation; Protocols documentation; Pyruvate; RF coil; Reliability of Results; Reproducibility; Resolution; Scanning; Selection for Treatments; Series; Signal Transduction; Source; Spectrum Analysis; Systolic heart failure; Techniques; Technology; Testing; Time; Translations; Validation; anaerobic glycolysis; clinical imaging; diabetic cardiomyopathy; experimental study; fatty acid metabolism; healthy volunteer; heart function; heart imaging; heart metabolism; human imaging; human subject; image reconstruction; imaging approach; imaging modality; imaging platform; imaging study; improved; in vivo; magnetic field; metabolic imaging; metabolomics; novel; pharmacokinetic model; physiologic model; reconstruction; response; single photon emission computed tomography; technology development; treatment response

Project Summary Heart disease is the leading cause of death in the US, resulting in over 600,000 deaths per year. The healthy heart is extremely metabolically active in order to supply its energetic needs, and alterations in cardiac metabolism have significant consequences for heart function. Metabolism is implicated in many heart diseases, including cardiomyopathies (hereditary hypertrophic cardiomyopathy, diabetic cardiomyopathy), diabetes, ischemia, HFpEF, and also as an early measure of systolic and diastolic heart failure. Measuring and quantifying heart metabolism would have significant implications on the diagnosis, understanding and management of these heart diseases, but there are no methods currently available to perform direct measurements of metabolism. This project aims to develop hyperpolarized 13C MRI as a human metabolic imaging for assessments of heart disease. This technology, utilizing 13C-pyruvate, has recently been shown to be safe and feasible in human subjects, with promising initial imaging in the heart. However, it still requires further development and in vivo validation to establish repeatable and reliable performance. This proposal includes Aim 1: Develop robust cardiac hyperpolarized 13C MRI methods. We propose imaging technology developments including real-time calibrations, fast imaging of multiple metabolites with whole heart coverage, image reconstructions with off-resonance correction, and cardiovascular signal models for quantifying metabolism. Aim 2: Perform in vivo validations in human subjects. We propose a series of studies that will establish robust imaging protocols and characterize the reproducibility and repeatability of this technique. These studies include evaluation of subject preparation methods, normalization of metabolic imaging data with correlative blood measurements, test-retest characterizations in healthy volunteers and patients, and same-session repeatability for multiple injection studies. The proposal also includes targeted performance measures to achieve with the proposed developments. Upon completion of this project, hyperpolarized 13C MRI has transformative potential for assessing heart diseases, adding new capabilities for quantifying metabolism in vivo.

项目摘要 心脏病是美国的主要死因，每年有超过60万人死于心脏病。 年。健康的心脏在新陈代谢方面非常活跃，以满足其能量需求， 心脏代谢的改变对心脏功能有重大影响。 代谢与许多心脏疾病有关，包括心肌病(遗传性 肥厚型心肌病、糖尿病心肌病)、糖尿病、缺血、HFpEF以及 作为收缩期和舒张期心力衰竭的早期测量。心脏的测量和量化 新陈代谢将对诊断、理解和 这些心脏病的管理，但目前还没有可用的方法来执行 直接测量新陈代谢。 该项目旨在开发超极化~(13)C磁共振成像作为人体代谢成像 对心脏病的评估。这项利用13C-丙酮酸的技术最近已经被证明 在人类受试者身上是安全可行的，在心脏上有希望的初始成像。然而， 它还需要进一步的开发和体内验证才能建立可重复和可靠的 性能。这项建议包括 目的1：建立稳健的心脏超极化~(13)C磁共振成像方法。我们建议进行成像 技术发展，包括实时校准，多种代谢物的快速成像 具有全心覆盖，具有非共振校正的图像重建，以及 量化新陈代谢的心血管信号模型。 目的2：在人类受试者身上进行体内验证。我们提出了一系列研究，这些研究将 建立稳健的成像方案，并表征其重复性和可重复性 技术。这些研究包括对受试者准备方法的评估，对 代谢成像数据与相关的血液测量，测试-重测特征 健康的志愿者和患者，以及多次注射研究的同一时段的重复性。 该提案还包括有针对性的业绩衡量，以实现与拟议的 事态的发展。在这个项目完成后，超极化13C磁共振成像具有变革性 评估心脏病的潜力，增加量化新陈代谢的新能力 活着。